As part of our COVID-19 Impact Series, we have been exploring potential impacts to our nationwide network of health system specialty pharmacies. Read More >


06/25/20 Diane Wolfe


By Diane Wolfe, RPh, National Director of Manufacturer Relations 

Like so many events, the 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO), scheduled for late May, transitioned to a virtual format in light of the COVID-19 outbreak. I was fortunate to be able to “attend” this year, for the first time. While the online format might not have been ideal for everyone, I enjoyed a remarkable experience learning more about drugs currently being studied in oncology. Key opinion leaders, scientists and manufacturers presented reviews and abstracts, highlighting the strength of the pipeline. The trend continues toward those drugs that become more targeted to both tumor mutations and those that treat orphan disease. 

Over the course of two days, I logged in to the Opening Session and a number of Highlights Sessions. I heard and/or read about a number of new products from Amgen, AstraZeneca, Janssen and other manufacturers. Highlights of some of the products covered are summarized in this article. I plan to continue to delve into the vast digital library of resources. For example, one area I am personally drawn to learning more about is gene therapy so I plan  to search out those abstracts in the near future 

All in all, the first virtual ASCO conference was a huge hit for me! ASCO will also present its 2020 Education Program on August 8–10 in a virtual format. I will most definitely plan to attend the Annual Meeting again in 2021. 

LinkedIn icon